Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Cyclically Adjusted Revenue per Share: HK$1.71 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09989 Shenzhen Hepalink Pharmaceutical Group Co Ltd HKSE:09989
84 GF Score
Price HK$4.16
GF Value HK$4.71
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted Revenue per Share?

Shenzhen Hepalink Pharmaceutical Group Co HKSE:09989 -0.95% 84 Cyclically Adjusted Revenue per Share is HK$1.71 as of Jun. 2026. GuruFocus rates HKSE:09989 with a GF Score™ of 84/100 and a GF Value™ of HK$4.71 (Modestly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Shenzhen Hepalink Pharmaceutical Group Co's adjusted revenue per share for the three months ended in Jun. 2026 was HK$0.980. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is HK$1.71 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Shenzhen Hepalink Pharmaceutical Group Co's average Cyclically Adjusted Revenue Growth Rate was 5.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Shenzhen Hepalink Pharmaceutical Group Co was 9.80% per year. The lowest was 3.40% per year. And the median was 6.00% per year.

As of today (2026-09-15), Shenzhen Hepalink Pharmaceutical Group Co's current stock price is HK$4.155. Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was HK$1.71. Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio of today is 2.43.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shenzhen Hepalink Pharmaceutical Group Co was 10.92. The lowest was 2.28. And the median was 5.37.


Shenzhen Hepalink Pharmaceutical Group Co  (HKSE:09989) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.155/1.71
=2.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shenzhen Hepalink Pharmaceutical Group Co was 10.92. The lowest was 2.28. And the median was 5.37.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted Revenue per Share Related Terms


Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted Revenue per Share Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.31 1.33 1.02 1.31 1.63

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.62 1.69 1.63 1.62 1.71

HKSE:09989 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio falls into.


HKSE:09989
84GF Score
Shenzhen Hepalink Pharmaceutical Group Co Ltd HKSE:09989
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Shenzhen Hepalink Pharmaceutical Group Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.98/116.0564*116.0564
=0.980

Current CPI (Jun. 2026) = 116.0564.

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201509 0.627 100.500 0.724
201512 1.017 100.600 1.173
201603 0.997 102.200 1.132
201606 0.494 101.400 0.565
201609 0.423 102.400 0.479
201612 0.563 102.600 0.637
201703 0.412 103.200 0.463
201706 0.541 103.100 0.609
201709 0.668 104.100 0.745
201712 0.920 104.500 1.022
201803 0.943 105.300 1.039
201806 1.216 104.900 1.345
201809 1.031 106.600 1.122
201812 1.341 106.500 1.461
201909 0.000 109.800 0.000
201912 0.000 111.200 0.000
202009 0.674 111.700 0.700
202012 1.427 111.500 1.485
202103 1.035 112.662 1.066
202106 1.512 111.769 1.570
202109 1.244 112.215 1.287
202112 1.440 113.108 1.478
202203 1.601 114.335 1.625
202206 3.091 114.558 3.131
202209 1.278 115.339 1.286
202212 1.322 115.116 1.333
202303 1.016 115.116 1.024
202306 1.075 114.558 1.089
202309 0.994 115.339 1.000
202312 1.018 114.781 1.029
202403 1.018 115.227 1.025
202406 1.075 114.781 1.087
202409 0.913 115.785 0.915
202412 0.893 114.893 0.902
202503 1.016 115.116 1.024
202506 1.046 114.907 1.056
202509 1.026 115.471 1.031
202512 0.960 115.832 0.962
202603 1.023 116.303 1.021
202606 0.980 116.056 0.980

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of HK$1.71 mean?
Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) has a Cyclically Adjusted Revenue per Share of HK$1.71 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors.
Is Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share too high?
Shenzhen Hepalink Pharmaceutical Group Co's current Cyclically Adjusted Revenue per Share is HK$1.71. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share of HK$1.71 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. Shenzhen Hepalink Pharmaceutical Group Co's current Cyclically Adjusted Revenue per Share is HK$1.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$4.71, compared to a current price of HK$4.16 — trading 11.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is HK$1.71. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989), the current Cyclically Adjusted Revenue per Share is HK$1.71 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Overvalued in 2026?

Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued. The current stock price of HK$4.16 is trading 11.8% below its estimated GF Value™ of HK$4.71. GuruFocus considers Shenzhen Hepalink Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for HKSE:09989:

  • Cyclically Adjusted Revenue per Share: HK$1.71
  • GF Value™: HK$4.71 vs. price of HK$4.16 (11.8% below fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the HKSE:09989 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shenzhen Hepalink Pharmaceutical Group Co Business Description

Other Exchanges 002399:China
Address No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
84GF Score

Get the complete analysis for HKSE:09989

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.16
Price
HK$4.71
GF Value